Supplemental Table.
Tier I | Tricyclic antidepressants | |||
Side effects | ||||
Common | Dry mouth; constipation; dizziness/orthostatic hypotension; urinary retention; sedation; blurred vision; weight loss (imipramine, desipramine); weight gain (amitriptyline, imipramine, desipramine); sexual side effects (imipramine) | Mechanism of action: SNRI | ||
T1/2 | ||||
Serious | Cardiac dysrhythmia; myocardial infarction; worsening depression and suicidality; may alter glucose regulation (imipramine, desipramine) | Amitriptyline | 9–27 h | |
Contraindications | MAOI use within 2 weeks; cardiac history (including recent MI, heart failure, and arrhythmias, prolonged corrected QT); glaucoma | Imipramine | 6–18 h | |
Desipramine | 7–60h | |||
Dosing | Pregnancy category: C-D* | |||
Starting | Amitriptyline | 10–25mg/day | Cost | |
Imipramine | 10–25mg/day | Amitriptyline | $ | |
Desipramine | 10–25mg/day | |||
Average effective | Amitriptyline | 100mg/day | Imipramine | $ |
Imipramine | 150mg/day | |||
Desipramine | 100 mg/day | |||
Titration | Weekly as tolerated | Desipramine | $$ | |
Monitoring | Generic available: Y | |||
Baseline | ECG for patients with history if cardiac disease or age >40 | |||
Periodic | Periodic screening for depression | |||
Special populations | ||||
Rental disease | Use with caution | DM medication drug-drug Interactions: N | ||
Liver disease | Use with caution | Hepatic metabolism | ||
Geriatrics | High risk (imipramine max dose should not exceed 100 mg/day in elderly patients) | |||
Tier I | Duloxetine | |||
Side effects | ||||
Common | Nausea; somnolence; dizziness; loss of appetite; constipation; may lower serum glucose; weight loss; weight gain; sexual side effects | Mechanism of action: SNRI | ||
Serious | Abnormal bleeding; hepatotoxicity; worsening depression/suicidality; serotonin syndrome | T1/2: 12h | ||
Contraindications | Uncontrolled narrow-angle glaucoma; concurrent treatment MAOI | Pregnancy category: C | ||
Dosing | Cost: $$$$ | |||
Starting | 20-60 mg/day | |||
Average effective | 60 mg/day | |||
Titration | As tolerated | |||
Monitoring | Generic available: N | |||
Baseline | Blood work: chemistry; liver function tests and glycated hemoglobin (HbAi c or A1C); screening for hypertension and depression | |||
Periodic | Periodic screening for depression | |||
Special populations | ||||
Rental disease | Dosage reduction may be required for mild to moderate renal impairment Not recommended for CrCI < 30 ml/min or ESRD | DM medication drug-drug Interactions: N | ||
Liver disease | Hepatic metabolism | Not recommended for use in hepatic impairment | ||
Geriatrics | No special dosing recommended | |||
Tier I | Pregabalin | |||
Side effects | ||||
Common | Dizziness; somnolence; peripheral edema; constipation; xerostomia; headache; weight gain | Mechanism of action: acts on voltage-gated calcium channels | ||
Serious | Angioedema | |||
Contraindications | Use with caution in patients with congestive heart failure | T1/2: 6.3 h | ||
Dosing | Pregnancy category: C | |||
Starting | 50 mg three times a day | |||
Average effective | 100 mg three times a day | Cost: $$ | ||
Titration | Can be rapidly titrated within a week | |||
Monitoring | Generic available: N | |||
Baseline | N/A | |||
Periodic | Periodic screening for depression | |||
Special populations | ||||
Rental disease | - |
DM medication drug-drug interactions: Y
|
||
Liver disease | Use with caution | Reduce total daily dose in proportion to renal impairment | ||
Geriatrics | No special dosing recommended | |||
Tier I | Gabapentin | |||
Side effects | ||||
Common | Dizziness; somnolence; weight gain; sexual side effects | Mechanism of action: unknown‡ | ||
Serious | Stevens-Johnson syndrome; worsening depression/suicidality | T1/2: 5–7h | ||
Contraindications | Pregnancy category: C | |||
Dosing | Cost: $$ | |||
Starting | 300mg/day every night or divided into three times a day | |||
Average effective | 800mg three times a day (maximum dose of 3600mg/day divided over three times a day) | |||
Titration | As tolerated | |||
Monitoring | Generic available: Y | |||
Baseline | N/A | |||
Periodic | Periodic screening for depression | |||
Special populations | ||||
Rental disease | Reduce total daily dose in proportion to renal impairment | DM medication drug-drug interactions: N | ||
Liver disease | – | |||
Geriatrics | – | |||
Tier II | Venlafaxine | |||
Side effects | ||||
Common | Nausea; somnolence; headache; weight loss; sexual side effects | Mechanism of action: SNRI | ||
Serious | Hyponatremia; gastrointestinal hemorrhage; bleeding abnormalities; neuroleptic malignant syndrome; serotonin syndrome; worsening depression/suicidality | T1/2:5±2h | ||
Contraindications | Recent MAOI use | Pregnancy category: C | ||
Dosing | Cost: $$$ | |||
Starting | Venlafaxine immediate release 37.5mg twice a day or venlafaxine extended release 75mg/day | |||
Average effective | Venlafaxine immediate release 112.5mg twice a day or venlafaxine extended release 150-225mg/day | |||
Titration | As tolerated | |||
Monitoring | Generic available: Y | |||
Baseline | Serum cholesterol; screening for hypertension and depression | |||
Periodic | Periodic screening for depression; blood pressure monitoring | |||
Special populations | ||||
Rental disease | Use with caution | Reduce total daily dose by 25% in mild to moderate renal impairment (CrC110-70 ml/min); reduce total daily dose by 50% if on hemodialysis | DM medication drug-drug interactions: N | |
Liver disease | Hepatic metabolism | Reduce total daily dose by 50% in mild to moderate renal impairment | ||
Geriatrics | No special dosing recommended but may benefit from lower initial dosing | |||
Tier II | Carbamazepine | |||
Side effects | ||||
Common | Dizziness; drowsiness; dry mouth; ataxia; nausea; vomiting; hyponatremia; pancytopenia; abnormal liver function; sexual side effects | Mechanism of action: inhibition of voltage-dependent sodium channels | ||
Serious | Dysrhythmia; congestive heart failure; Stevens-Johnson syndrome; toxic epidermal necrolysis; nephrotoxicity; hypocalcemia, hyponatremia; blood dyscrasia including aplastic anemia | T1/2:12–17h | ||
Contraindications | Blood dyscrasias; dermatologie reactions; presence of HLA-B*1502 allele is a contraindication, however guidelines for routine screening of Asian patients has not been established | Pregnancy category: D | ||
Dosing | Cost: $$$ | |||
Starting | 200mg/day | |||
Average effective | 300mg/day or twice a day | |||
Titration | Over 2 weeks | |||
Monitoring | Generic available: Y | |||
Baseline | Complete blood count; liver function tests; chemistry; thyroid function tests; screening for depression | |||
Periodic | Complete blood count; liver function tests; chemistry; thyroid function tests; carbamazepine levels§; screening for depression |
DM medication drug-drug interactions: Y
|
||
Special populations | ||||
Rental disease | Use with caution | No dose adjustment recommended | ||
Liver disease | Hepatic metabolism; Use with caution | No dose adjustment recommended | ||
Geriatrics | No special dosing recommended | |||
Tier II | Valproate | |||
Side effects | ||||
Common | Headache; somnolence; dizziness; nausea; dyspepsia; abdominal pain; tremor; hair loss; weight loss; weight gain | Mechanism of action:increases effects at GABA | ||
Serious | Pancreatitis; thrombocytopenia; hepatic failure | receptor | ||
T1/2: 9–16h | ||||
Contraindications | Hepatic failure; pancreatitis; urea cycle disorders | Pregnancy category: D|| | ||
Dosing | Cost: $$ | |||
Starting | 500mg/day or 300 mg twice a day | |||
Average effective | 500–600 mg twice a day | |||
Titration | As tolerated | |||
Monitoring | Generic available: Y | |||
Baseline | Liver function tests; complete blood count; prothrombin time; partial thromboplastin time; ammonia; screening for depression | |||
Periodic | Liver function tests; complete blood count; prothrombin time; partial thromboplastin time; ammonia; valproate levels; screening for depression | |||
Special populations | ||||
Rental disease | No significant effect on metabolism, however Rental disease may influence protein binding and clearance | DM medication drug-drug interactions: N | ||
Liver disease | Hepatic metabolism | Use with caution Dose reduction required Contraindicated in severe liver disease | ||
Geriatrics | No special dosing recommended but may benefit from lower initial dosing | |||
Tier III | Oxcarbazepine | |||
Side effects | ||||
Common | Abdominal pain; nausea; vomiting; ataxia; dizziness; headache; nystagmus; somnolence; tremor; vertigo; diplopia; rhinitis; fatigue; weight loss; weight gain | Mechanism of action:oxcarbazepine and its active metabolite monohydroxy metabolite block voltage-sensitive sodium channels and modulate voltage-activated calcium channels | ||
Serious | Hyponatremia; Stevens-Johnson syndrome; toxic epidermal necrolysis; angioedema | |||
Contraindications | – | |||
Dosing | T1/2: oxcarbazepine 2h; monohydroxy metabolite (active metabolite) 9h | |||
Starting | 300mg/day | |||
Average effective | 1200mg/day divided into twice or three times a day dosing | Pregnancy category: C | ||
Titration | Weekly titration to twice a day dosing Slow titration for patients with CrCI < 30ml/min | Cost: $$$$$ | ||
Monitoring | Generic available: Y | |||
Baseline | Serum sodium | |||
Periodic | Serum sodium; periodic screening for depression | |||
Special populations | ||||
Rental disease | For CrCI <30ml/min: initial dose should be half the starting dose with slow titration | DM medication drug-drug interactions: N | ||
Liver disease | Hepatic metabolism | No dose adjustment recommended for mild to moderate impairment. No data available for severe liver disease | ||
Geriatrics | No special dosing recommended | |||
Tier III | Lamotrigine | |||
Side effects | ||||
Common | Nausea; abdominal pain; headache; drowsiness; dizziness; weight loss | Mechanism of action: stabilization of neural membranes through voltage-gated sodium channels; and inhibition of presynaptic release of glutamate | ||
Serious | Stevens-Johnson syndrome; toxic epidermal necrolysis; hepatic failure; anemia/thrombocytopenia/pancytopenia | |||
Contraindications | – | |||
Dosing | ||||
Starting | 25mg/day | T1/2:25–33h | ||
Average effective | 150–200 mg twice a day | Pregnancy category: C | ||
Titration | Slow; 25mg increase per week. More rapid titration is contraindicated because of concern for Stevens-Johnson syndrome | Cost: $$$$$ | ||
Monitoring | Generic available: Y | |||
Baseline | N/A | |||
Periodic | Periodic screening for depression and rash | |||
Special populations | ||||
Rental disease | Renal metabolism | Use with caution; dosage reduction may be required | DM medication drug-drug interactions: N | |
Liver disease | Hepatic metabolism | Use with caution; dosage reduction may be required | ||
Geriatrics | No special dosing recommended | |||
Tier III | Alpha lipoic acid | |||
Side effects | ||||
Common | Paresthesias; muscle cramps; platelet dysfunction; headache; rash; nausea; vomiting; vertigo | Mechanism of action: antioxidant | ||
Serious | Hypoglycemia | T1/2:30min | ||
Contraindications | Unknown | Pregnancy category: unknown | ||
Dosing | Cost ¶: N/A | |||
Starting | 300mg twice a day (or 200mg three times a day) | |||
Average effective | 600mg once daily or divided twice a day | |||
Titration | N/A | |||
Monitoring | Generic available: N/A | |||
Baseline | Unknown | |||
Periodic | Periodic screening for depression | |||
Special populations | ||||
Rental disease | Unknown | DM medication drug-drug interactions: unknown; may interact with insulin and oral hypoglycemics | ||
Liver disease | Unknown | |||
Geriatrics | Unknown | |||
Breakthrough pain | Lidocaine patch | |||
Side effects | ||||
Common | Local skin irritation; itching; edema; rash; urticaria; blisters; angioedema | Mechanism of action: decreased neuronal membrane permeability to sodium ions | ||
Serious | Allergic/anaphylactoid reaction | |||
Contraindications | Skin breakdown in area of application | |||
Dosing | ||||
Starting | One patch applied to painful area. Patch may remain in place for up to 12h in any 24h period | T1/2: unknown# | ||
Average effective | As above | Pregnancy category: B | ||
Titration | N/A | Cost**: $$$$$ | ||
Monitoring | Generic available: N | |||
Baseline | N/A | |||
Periodic | Check skin for reactions at site of patch | |||
Special populations | ||||
Rental disease | No special dosing recommended | DM medication drug-drug interactions: N | ||
Liver disease | No special dosing recommended | |||
Geriatrics | No special dosing recommended | |||
Breakthrough pain | Capsaicin | |||
Side effects | ||||
Common | At site of application: itching; burning; stinging; erythema; cough; nausea | Mechanism of action: depletes stores of peripheral nerve substance P and prevents reaccumulation | ||
Serious | Hypertension | |||
Contraindications | Skin breakdown in area of application | |||
Dosing | T1/2: 1.64h | |||
Starting | N/A | Pregnancy category: C | ||
Average effective | 0.075% capsaicin patch or cream applied 3-4 times per day PRN | Cost‡‡: $–$$$ | ||
Titration | N/A | |||
Monitoring | Generic available: Y | |||
Baseline | N/A | |||
Periodic | Check skin for reactions at site of patch | |||
Special populations | ||||
Rental disease | No special dosing recommended | DM medication drug-drug interactions: N | ||
Liver disease | No special dosing recommended | |||
Geriatrics | No special dosing recommended | |||
Breakthrough pain | Tramadol | |||
Side effects | ||||
Common | Flushing; pruritus; constipation; nausea; vomiting; dyspepsia; xerostomia; dizziness; headache; somnolence; insomnia; weight loss; sexual side effects | Mechanism of action: tramadol and its active metabolite bind to central u-opiate receptors and inhibit ascending pain pathways; also inhibits serotonin and norepinephrine reuptake. | ||
Serious | Dyspnea; respiratory depression; myocardial infarction; pancreatitis; seizure; serotonin syndrome | |||
Contraindications | Acute intoxication with CNS depressants (alcohol, hypnotics, opioids, or psychotropic drugs) | |||
Dosing | T1/2: §§ tramadol: −6–8h; active metabolite: 7–9h | |||
Starting | 50mg/day PRN | |||
Average effective | 50–200mg/day divided twice daily PRN | Pregnancy category: C | ||
Titration | To be used PRN | Cost: $|||| | ||
Monitoring | Generic available: Y | |||
Baseline | N/A | |||
Periodic | Monitor for tolerance and abuse | |||
Special populations | ||||
Rental disease | For CrCI <30ml/min:
|
DM medication drug-druginteractions: N | ||
Liver disease | Hepatic metabolism | For cirrhosis:
|
||
Geriatrics | Use with caution |
|
Imipramine is pregnancy category D.
May act on voltage-gated calcium channels and impact the release of excitatory neurotransmitters.
Owing to hepatic autoinduction, serum levels must be monitored until stable.
Known teratogen.
Prices vary based on distributors.
Half-life of topical lidocaine is not known. It is not clear if it is metabolized in the skin. The half-life of intravenous lidocaine is 1.5-2.5 hours.
Cost listed is for 30 patches of Lidoderm.
Cost based on price per tube of 0.075% capsaicin cream or packages of four patches used four times a day although this is not the recommended dosing.
T1/2: prolonged in elderly, hepatic and renal impairment.
Listed cost is for 90 tablets of 50mg tramadol immediate release.
Key for costs: $, US$0-50; $$, US$51-100; $$$, US$101-150; $$$$, US$151-200; $$$$$, >US$201. CrCI, creatinine clearance; DM, diabetes mellitus; ESRD, end-stage Rental disease; MAOI, monoamine oxidase inhibitors; MI, myocardial infarction; PRN, pro re nata; SNRI, serotonin-norepinephrine reuptake inhibitor.